Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2020-05-29
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 270
- Registration Number
- NCT04408638
- Locations
- 🇵🇱
Uniwersytecki Szpital Kliniczny; Klinika Hematologii, Terapii Komórkowych i Chorób Wewn?trznych, Wroc?aw, Poland
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Community Cancer Institute (CCI), Fresno, California, United States
A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).
- Conditions
- Interventions
- First Posted Date
- 2020-05-27
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 6
- Registration Number
- NCT04404140
- Locations
- 🇫🇷
Gustave Roussy, Villejuif, France
🇪🇸Hospital Ramon y Cajal; Servicio de Oncologia, Madrid, Spain
🇫🇷Centre Val Aurelle Paul Lamarque; Radiotherapie, Montpellier, France
A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1382
- Registration Number
- NCT04374253
- Locations
- 🇺🇸
Research Center for Clinical Studies, Inc., Norwalk, Connecticut, United States
🇺🇸Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Infinity Clinical Research, LLC, Sunrise, Florida, United States
A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia
- First Posted Date
- 2020-04-27
- Last Posted Date
- 2022-08-31
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 97
- Registration Number
- NCT04363736
- Locations
- 🇺🇸
St Joseph's Regional Medical Center, Wayne, New Jersey, United States
🇺🇸St. Jude Medical Center, Fullerton, California, United States
🇺🇸Advocate Christ Medical Center, Oak Lawn, Illinois, United States
A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.
- First Posted Date
- 2020-04-10
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT04341259
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai City, China
A Study to Evaluate the Safety and Tolerability of Long-term Administration of Gantenerumab in Participants With Alzheimer's Disease (AD)
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 116
- Registration Number
- NCT04339413
- Locations
- 🇦🇷
Instituto Neurologia Bs As, Ciudad Autonoma Buenos Aires, Argentina
🇯🇵Juntendo University Urayasu Hospital; Neurology, Chiba, Japan
🇵🇱NZOZ NEURO-KARD Ilkowski i Partnerzy Sp. Partn. Lek, Pozna?, Poland
A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 522
- Registration Number
- NCT04338269
- Locations
- 🇺🇸
Texas Oncology - Central South, Austin, Texas, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
A Study Evaluating Safety, Pharmacokinetics, Pharmacodynamics, And Clinical Activity Of RO7119929 (TLR7 Agonist) In Participants With Unresectable Advanced Or Metastatic Hepatocellular Carcinoma, Biliary Tract Cancer, Or Solid Tumors With Hepatic Metastases
- Conditions
- Interventions
- First Posted Date
- 2020-04-08
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 55
- Registration Number
- NCT04338685
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇺🇸City of Hope Cancer Center, Duarte, California, United States
🇭🇰Queen Mary Hospital; Dept of Medicine, Hong Kong, Hong Kong
A Study to Investigate the Efficacy and Safety of Atezolizumab (Tecentriq) in Previously-Treated Patients With Advanced Thymic Carcinoma
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 34
- Registration Number
- NCT04321330
- Locations
- 🇨🇳
West China Hospital, Sichuan University; Department of Breast, Chengdu, China
🇨🇳Sichuan Cancer Hospital, Chengdu City, China
🇨🇳The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia
- First Posted Date
- 2020-03-25
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 452
- Registration Number
- NCT04320615
- Locations
- 🇺🇸
Ochsner Clinic Foundation, Baton Rouge, Louisiana, United States
🇺🇸Robert Wood Johnson University Hospital/Rutgers, New Brunswick, New Jersey, United States
🇨🇦University Health Network, Toronto, Ontario, Canada